X

Albert David Ltd. Stock Analysis

Small Cap
Evaluated by 538 users | BSE: 524075 | NSE: ALBERTDAVD |
Pharmaceuticals & Drugs
Albert David was incorporated in the year 1938. The company is a part of Kothari group.Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed 11.4%10.8%8.87%9.14%12.04%11.94%14.6%7.65%3.38%7.28%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 203220231265291322323295290317
Y-o-Y Gr. Rt.-8.3%5.2%14.7%9.7%10.7%0.3%-8.5%-1.7%9.3%
Adjusted EPS (Rs.) 17.9418.4513.3214.4121.7323.0433.2923.711.3826.03
Y-o-Y Gr. Rt.-2.8%-27.8%8.2%50.8%6%44.5%-28.8%-52%128.7%
Book Value per Share (Rs.) 110.47124.25132.38142.11158.29162.64239.75320.67325.81368.74
Adjusted Net Profit 10.210.57.68.212.413.21913.56.514.9
Net Op. Cash Flow (Rs. Cr.) 16.924.610.920.220.827.86819.93032
Debt to Cash Flow from Ops 3.271.923.651.872.031.080.31.510.920.01
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Albert David Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 5.1%1.8%-0.6%9.3%
Adjusted EPS 4.2%3.7%-7.9%128.7%
Book Value per Share 14.318.415.413.2
Share Price 16.5% 7.5% 14.2% 14.8%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) 17.2315.7210.3810.514.4614.3616.558.463.527.5
Operating Profit Margin (%) 13.6112.8610.3710.0411.311.499.716.645.99.38
Net Profit Margin (%) 5.044.793.293.14.274.095.894.582.244.68
Debt to Equity 0.880.660.530.470.470.320.150.160.150
Working Capital Days 169161150143160174161194226203
Cash Conversion Cycle 36354045496062625334
Entity Percentage Holding
Promoters 61.16%
Institutions 3.89%
Non-Institutions 34.95%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Albert David's performance infers:

Albert David earnings have grown by 3.7%, whereas share price has appreciated 7.5% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Albert David share prices over the last 10 years. Here is what we found out:

Albert David share price has appreciated 11.6% annually over the past ten years.

Albert David was incorporated in the year 1938. The company is a part of Kothari group.

Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil,

Albert David was incorporated in the year 1938. The company is a part of Kothari group.

Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.

It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.

The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.

The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.

ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.

Products offered by the Company:

The company is operating in major therapeutic segments that include:

  • Analgesics/AntiInflammatory
  • Anti-Bacterials
  •  Anti-Ulcerants
  •  Dermatologicals
  • Anxiolytics
  • Large Volume Parenteral
  •  Disposable Syringes & Needles
  • Herbal Drugs
  • Nutrition
  • Neurotropics
  •  Placental Extracts
  •  Anthelmintic
  • Haemostati
  • Cough Preparations
  • Laxatives
  • Skeletal Relaxants
  • Anti-Arthiritic / Chondroprotective Agents.

Future Plans:

  • The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
  • It will concentrate on product line extension for its flagship brand Placentrex by bringing in newer formulations and looking for a new therapeutic area of usage.
  •  Future expansion in the herbal product range will be focused in the area of women`s healthcare.
  • ADL is planning to enter newer therapeutic areas like dermatological and ophthalmological segments.
  • Furthermore, it will also strengthen its presence in the gastrointestinal segments and in the areas of pain management.
  •  The company is also planning to launch newer products in the areas of nutritional, gynaecological and herbal medicine.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback